Axonics (AXNX)
(Delayed Data from NSDQ)
$67.13 USD
+0.12 (0.18%)
Updated May 30, 2024 04:00 PM ET
After-Market: $67.10 -0.03 (-0.04%) 6:38 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Axonics Modulation Technologies (AXNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$71.00 | $75.00 | $63.00 | 5.95% |
Price Target
Based on short-term price targets offered by 11 analysts, the average price target for Axonics Modulation Technologies comes to $71.00. The forecasts range from a low of $63.00 to a high of $75.00. The average price target represents an increase of 5.95% from the last closing price of $67.01.
Analyst Price Targets (11)
Broker Rating
Axonics Modulation Technologies currently has an average brokerage recommendation (ABR) of 2.62 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 13 brokerage firms. The current ABR compares to an ABR of 2.46 a month ago based on 13 recommendations.
Of the 13 recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 15.38% and 7.69% of all recommendations. A month ago, Strong Buy made up 23.08%, while Buy represented 7.69%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 10 | 10 | 9 | 9 | 9 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.62 | 2.62 | 2.46 | 2.46 | 2.46 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
5/14/2024 | C.L. King & Associates | Kristen M Stewart | Hold | Hold |
5/6/2024 | Needham & Company | Michael Matson | Hold | Hold |
5/1/2024 | Piper Sandler | Adam C Maeder | Hold | Hold |
3/4/2024 | Mizuho SecuritiesUSA | Anthony Petrone | Strong Buy | Strong Buy |
1/17/2024 | Truist Securities | Richard Newitter | Hold | Hold |
1/12/2024 | Robert W. Baird & Co. | David Rescott | Strong Buy | Hold |
1/12/2024 | SVB Securities | Michael Kratky | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.62 |
ABR (Last week) | 2.62 |
# of Recs in ABR | 13 |
Average Target Price | $71.00 |
LT Growth Rate | NA |
Industry | Medical Info Systems |
Industry Rank by ABR | 90 of 252 |
Current Quarter EPS Est: | 0.08 |